Table 1 Patients baseline characteristics
No. of patients | 173 |
Follow-up median (min-max) [months] | 27.5 (0.4-200.8) |
Gender: males-females | 37.5%-62.5% |
Age median (range) [years] | 64 (30–84) |
ISS stage: I-II-III | 30.3%-31.9%-37.8% |
Durie-Salmon stage: I-II-III | 6.5%-14.6%-78.9% |
Durie-Salmon substage: A-B | 79.8%-20.2% |
Ig isotype: IgG-IgA-IgM-FLC-NonSecr. | 62.3%-23.6%-0.9%-12.3%-0.9% |
Light chains: kappa-lambda | 66%-34% |
No. of previous treatment lines | |
    None (First line treatment) | 79 (56.0%) |
    One | 18 (12.8%) |
    Two | 16 (11.3%) |
    More (>2) | 28 (19.9%) |
Treatment regimen | |
    Bortezomib | 50 (43.1%) |
    Thalidomid | 40 (34.5%) |
    Lenalidomide | 26 (22.4%) |
Biochemical parameter | |
    Haemoglobin (g/l) | 103.5 (73–157) |
    Thrombocytes (count x109) | 193 (33–416) |
    Calcium (mmol/l) | 2.3 (0.0-13.9) |
    Albumin (g/l) | 38.3 (3.76-50.4) |
    Creatinine (umol/l) | 101 (11–932) |
    β2-microglobulin (mg/l) | 4.07 (1.1-42.6) |
    Lactate dehydrogenase (ukat/l) | 3.39 (1.71-30.89) |
    C-reactive protein (mg/l) | 4.15(0–174.3) |
    Monoclonal Ig (g/l) | 31.05 (0–95.6) |
    Plasma cell infiltration of bonemarrow (%) | 32.8 (1.6-93.6) |
Chromosomal abnormality | |
    13q14 deletion | 75 (55.1%) |
    17p13 deletion | 19 (13.6%) |
    Translocation t(4;14) | 18 (14.3%) |
    1q21 gain | 64 (46.7%) |
    Hyperdiploidy | 55 (42.0%) |